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Abstract <250 words (249) 
Objectives:  To evaluate the efficacy of next generation sequencing for diagnosing 
congenital muscular dystrophies (CMD). 
 
Methods:  A cohort of 124 CMD patients was investigated using histological and 
immunohistochemical staining of muscle biopsies, candidate gene sequencing and next 
generation sequencing (NGS).   
 
Results:  Traditional diagnostic methods identified a deficiency of merosin, D-dystroglycan 
or collagen VI in 51% of our CMD cohort.  Candidate gene sequencing led to a genetic 
diagnosis in 34%.  During 2013-15, investigation of 33 undiagnosed CMD patients with NGS 
yielded a diagnosis in 67% (22/33 patients).  The diagnoses within the cohort were 
heterogeneous: five patients had variants in novel (PIGY and GMPPB) or recently published 
genes (GFPT1 and MICU1); seven had variants in TTN or RYR1, large genes technically 
difficult to Sanger sequence; 43 patients (73%) had variants in genes known to cause CMD, 
but 11 patients (17%) had variants in genes associated with congenital myopathies, reflecting 
the overlapping clinical and histological features of these conditions.  Together, a NGS 
neuromuscular gene panel and chromosomal microarray (CMA) could diagnose 95% of the 
patients in the cohort.   
 
Conclusions: This study supports using targeted NGS as a first line tool to diagnose CMD, 
avoiding a muscle biopsy and associated delay to genetic diagnosis.  Muscle biopsy should be 
reserved as a second tier investigation.  The next phase of diagnostic testing for undiagnosed 
patients will include whole genome sequencing and RNA sequencing, and will depend on 
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expanding international collaborations and data sharing to increase recognition and 
confirmation of possible pathogenic variants in new disease genes. 
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Introduction <250 words (212 words) 
 
The congenital muscular dystrophies (CMDs) are inherited disorders of skeletal muscle 
characterized by hypotonia and weakness within the first 2 years of life, delayed gross motor 
milestones and dystrophic features on skeletal muscle biopsy (1,2).  These disorders are 
phenotypically diverse and genetically heterogeneous.  The boundaries between CMD, 
congenital myopathies and limb girdle muscular dystrophies are blurred, with overlap in 
disease genes, clinical presentation and histopathological features.   
 
In 2008, Peat and colleagues published the protein and molecular diagnostic workup of a 
Australasian CMD cohort (2).  The diagnostic methods, muscle immunohistochemistry and 
Sanger sequencing of candidate genes, were described as “state-of-the-art” in an 
accompanying editorial (3).  An immunohistochemical classification was achieved in 45% 
(45/101) of the cohort and a genetic diagnosis in 24% (24/101).  The advent of ‘next 
generation sequencing’ (NGS) has contributed to a rapid increase in the number of known 
CMD genes from 12 in 2008, to 28 in 2015 (4).  However, the diagnostic yield of next 
generation sequencing by panel testing of known disease genes, whole exome, or whole 
genome approach remains uncertain. 
 
This study evaluates the diagnostic outcomes in 124 CMD patients ascertained over 35 years.  
NGS approaches in 33 unsolved patients provided a genetic diagnosis for 22/33 (67%) 
patients, double the diagnostic efficacy achieved using traditional approaches of 
immunostaining and Western blot that were considered state-of-the-art in 2008.  
 
Methods  (539 words) 
O’Grady      Page      10 
Patient Ascertainment 
CMD patients were identified retrospectively and prospectively through clinical records and 
the Institute for Neuroscience and Muscle Research (INRM) biospecimen bank.  Clinical 
examination, review of medical records, muscle histology and complementary investigations 
such as brain MRI and muscle imaging were used to define the clinical phenotype of affected 
individuals.    
 
Inclusion Criteria: Evidence of muscle weakness and hypotonia within the first 2 years of 
life and clinical features consistent with congenital muscular dystrophy, such as delayed 
gross motor milestones, congenital/early contractures or scoliosis, brain MRI consistent with 
laminin-α2 deficiency or α-dystroglycanopathy, or a raised CK (>200 IU/L).  Only the 
proband was included when more than one sibling was affected.  Patients with a muscle 
biopsy performed between 1979 and 2014 were included if it showed dystrophic changes, or 
non-specific myopathic findings provided the clinical criteria were met.  A small number of 
patients were not investigated with a muscle biopsy.  Deliberately broad inclusion criteria 
were chosen to reflect the variable pathology which can occur early in the course of disease, 
secondary to selective muscle involvement and in specific subtypes such as collagen VI 
myopathies (5,6).  
 
Inclusion in NGS studies was based on phenotype with preference given to families with 
multiple affected siblings and those with DNA available from the proband and parents.  
Inclusion of retrospective members of the cohort was limited by the need for additional 
consent and the availability of DNA samples.  Given the elapsed time, it was considered 
insensitive to re-contact some families and some were no longer contactable.  
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Exclusion criteria: Structural changes in skeletal muscle diagnostic of a congenital 
myopathy, for example rods or cores.  Eleven fetuses and neonatal deaths ascertained in the 
Peat cohort (2) were excluded because they had not been investigated further and were no 
longer contactable.   
 
Standard Protocol Approvals and Patient Consents 
Ethics approval for all aspects of this study was obtained from the Human Research Ethics 
Committee of the Sydney Children’s Hospitals Network (Approval No: 10.CHW.45).  
Written informed consent was obtained from all participants and inclusion in NGS studies 
was dependent on completion of an additional specific consent, reflecting the complexities of 
NGS analysis.   
 
Immunohistochemical analysis 
Immunohistochemical staining of the muscle biopsy for laminin-α2, glycosylated α-
dystroglycan and collagen VI, was performed using previously reported methods (2).  
Probands were classified as α-dystroglycanopathy, collagen VI-related myopathy or laminin-
α deficient if their biopsy showed moderate to severely reduced or absent staining.   
 
Candidate gene sequencing 
Candidate gene sequencing was guided by phenotype and immunohistochemical analysis.  
Methods have been previously reported for FKRP(2), LARGE, POMT1, POMT2, FKTN and 
POMGNT1(7), the three collagen VI genes (8), LAMA2 (9), SEPN1 (10), LMNA (11)  and 
DNM2 (12).  
 
Next generation sequencing (NGS) 
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Targeted NGS was performed with either a research-based 45 gene panel (Panel A) (13) , or a 
commercial 345 gene panel (Panel B) offered by PathWest Laboratory, Australia (Table e2).  
WES was performed by the Broad Institute using previously published methods (11).  WGS 
was performed on 3 probands who did not have a diagnosis following WES.  
 
Whole exome sequencing analysis pipeline.  
Variant filtering was performed using the xBrowse web browser 
(https://atgu.mgh.harvard.edu/xbrowse).  Variants were identified as outlined in Figure 1.  
Likely pathogenic variants were confirmed by Sanger sequencing in the proband and family 
members.   
 
Results (1157) 
Traditional approaches of immunostaining, Western blot and candidate gene sequencing 
provided a genetic diagnosis in 34%. 
 
A cohort of 124 CMD patients was ascertained; 90 were part of the 1979-2006 cohort 
published by Peat and colleagues (2), and a further 34 probands were ascertained between 
2006 and 2014 (Figure 2);  61 probands were female and 63 were male; 101 came from non-
consanguineous families, 15 from consanguineous families and for 8 probands this 
information was not available.  Eight probands had affected siblings.    
 
Muscle histology was available for 118 probands.  The median duration from onset of 
symptoms to muscle biopsy was 18 months.  Immunohistochemical analysis was performed 
on 114 muscle biopsy specimens; 58 probands (51%) could be classified on the basis of a 
moderate or severe reduction in collagen VI, laminin-α2 or α-dystroglycan (Figure 3 
Comment [GO1]: Is there a better reference, or include as supplemental methods. 
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(online)).  Candidate gene sequencing was performed on the basis of clinical phenotype and 
immunohistochemical classification in 91 probands (Figure 3 (online)).   The mean number 
of genes sequenced was 4 (range 1-16).   
 
Using muscle biopsy and histological examination, immunohistochemical analysis, candidate 
gene sequencing and chromosomal microarray (CMA) a genetic diagnosis was achieved for 
41 of 122 probands (33.6%) (Table e1 (online)).  Two patients had clinical and 
immunohistochemical findings consistent with the genetic diagnosis (Patient 33 with 
abnormal DDG and Patient 71 with abnormal laminin-α2); however; only a heterozygous 
variant was identified on sequencing.  In two patients the diagnosis was made by CMA.  
 
Next Generation Sequencing produces a genetic diagnosis in 22/33 (66.6%) CMD patients 
unsolved using traditional diagnostic approaches 
 
Of the 80 probands who remained undiagnosed after conventional investigation, 31 were 
available for inclusion in NGS studies (Figure 2).  Two families declined participation and 
the remaining families were not contactable.  Two recently ascertained probands (Patient 117 
and 118) were investigated by NGS without a muscle biopsy or candidate gene sequencing. 
 
Eleven patients were investigated with a NGS neuromuscular gene panel (Panel A – 6, Panel 
B – 4, both - 1) and 22 with WES.  DNA from the parents was included in WES studies in 19 
cases and in three cases affected or unaffected siblings were included.  Diagnoses were made 
in 22/33 (66.6%) (18 confirmed, 1 possible and 3 unpublished novel findings) (Table e1 
(online)).  Ten were diagnosed by NGS panel and 12 by WES. 
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The subgroup investigated with NGS had remained undiagnosed despite extensive research-
based candidate gene sequencing and was thus enriched for gene discovery. Two probands 
had variants in GMPPB, contributing to identification of this gene as a cause of α-
dystroglycanopathy (14,15).  Patient 44, and her affected sister, had homozygous recessive 
variants in PIGY, and a novel multisystem disease secondary to a deficiency of GPI anchor 
biosynthesis (16).  A homozygous recessive variant in ACTA1 was identified as a cause of 
rigid spine muscular dystrophy, a new phenotype of ACTA1-related disease (13).  Three 
strong candidate genes are not yet published.  Two patients had causative variants in genes 
published after enrolment in this study (GFPT1 and MICU1) (17,18). 
 
NGS also facilitated diagnosis of RYR1 or TTN-related disease in 5 patients.  Both genes are 
large and have previously been technically difficult to Sanger sequence.   
 
In Patient 99 a heterozygous missense variant in LARGE was identified by WES.  His 
phenotype was consistent with α-dystroglycanopathy.  CMA detected a ..kb intragenic 
deletion of LARGE (22q12.3(33,774,511-34,221,251)) inherited in trans, highlighting the 
complementary nature of these investigations.   
 
Data from WGS was available for 3 probands undiagnosed despite WES.  To date this has 
not yielded a genetic diagnosis for these patients; however, optimization of bioinformatics is 
continuing.  Patient 107 had a retrogene insertion in MTMR2 of uncertain significance.   
 
For the 63 probands who obtained a genetic diagnosis, the median age at diagnosis was 10 
years (range 18 months – 42 years).  The two probands investigated by NGS without muscle 
biopsy (Patient 117 and 118) had a genetic diagnosis 18 and 30 months after initial 
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presentation.  The inheritance was de novo dominant in 25 probands, recessive in 37 
probands, and X-linked in 1.    
 
Genetic diagnoses within the cohort are heterogeneous 
73% (46/63) diagnosed probands had variants in a recognized CMD gene (Figure 4).  In 
41/46 the gene was well known prior to this study (FKRP, FKTN, LARGE (2), POMGNT1, 
POMT1 (2), POMT2 (2), LAMA2 (8); COL6 (16), LMNA (6), and SEPN1 (2)).  In the 
remaining 5, the gene was identified as causing CMD during, or as a result of this study 
(GMPPB (2), MICU1, ACTA1 and PIGY).  
 
Eleven probands (17%) had variants in genes known to be associated with congenital 
myopathies (DNM2 (2), RYR1 (4), SIL1 (1), ACTA1 (1), and TTN (3)). Patient 60 had variants 
in GFPT1, a recently published cause of a limb girdle myasthenia (17).  
 
Biochemical and pathological features predict likelihood of a genetic diagnosis  
Creatine kinase (CK) measurements were available for 114 probands. Forty probands had CK 
levels >1000 IU/L on at least one occasion, 24 had mild elevation (200-1000 IU/L) and 50 
had normal levels.  A genetic diagnosis was more likely to be obtained in those with a CK 
>200 IU/L (42/64, 65.6%) compared with those with a normal CK (20/50, 40%) (p=0.003).  
A diagnosis was also more likely, in those with a CK 200-1000 IU/L, than >1000 IU/L 
(19/24 compared with 23/40; p=0.039).  Of the 16 patients with collagen VI-related CMD, 13 
had a CK measuring ~200-1000 IU/L, none had a level >1000 IU/L, and 3 had normal levels.   
 
Histological data was available for 119 probands.  In 81 the muscle biopsy was classified as 
dystrophic, in 34 it was non-specific and in 3 it was normal.  Probands with a dystrophic 
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muscle biopsy were more likely to achieve a genetic diagnosis than patients with a non-
dystrophic or normal biopsy (49/81 (61%) compared with 10/37 (27%); p=0.0004).  
 
Both factors are considered in Table 2.  Elevated CK predicted a gene traditionally associated 
with CMD.  All patients with LAMA2-related CMD, α-dystroglycanopathies, LMNA-related 
CMD, 1/2 with SEPN1-related CMD and 12/15 with collagen VI myopathies were within this 
group.  Interestingly, the group of patients with dystrophic biopsies but normal CK included 
patients with mutations in TTN, RYR1, and DNM2.  These genes are known to be associated 
with histological findings that mimic dystrophic findings, such as centralized nuclei and fibre 
size variation. 
 
Immunohistochemical analysis accurately predicts CMD subtype  
A classification could be made on the basis of immunohistochemical analysis for 58/114 
probands (51%) (Figure 3 (online)).  Causative variatnts were identified in COL6A1, 
COL6A2 or COL6A3 in 14/21 probands (67%) classified as having a collagen VI-related 
disorder.  Only one proband (Patient 58) was missed by this classification, because the 
collagen VI reduction was classified as mild, rather than moderate or severe.  Recessive 
variants in LAMA2 were found in 7/11 (64%) probands classified as having laminin-α2 
deficiency.  Patient 71 had a heterozygous variant only identified by Sanger sequencing and 
did not have WES.  No LAMA2 patients were missed by this classification.   
A genetic diagnosis was confirmed for 16/26 probands classified as having an α-
dystroglycanopathy.  Ten (38%) had variants in genes known to cause α-dystroglycanopathy 
(FKRP-1; FKTN-1; LARGE -2; POMGNT1-1; POMT1-2, POMT2-2 ; GMPPB-1) and 6 
(23%) had variants in other genes (DNM2-2; GFPT-1; RYR1-3).  One patient with a GMPPB 
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mutation was missed by this classification because of mild rather than moderate or severe 
reduction of α-dystroglycan.  
 
Overall, a genetic diagnosis was more likely in the group with an immunohistochemical 
classification (39/58; 67%) compared with the group who could not be classified (19/56; 
34%) (p=0.0002). 
 
DISCUSSION 1123 
This study describes a cohort of 124 potential CMD patients referred to a specialist 
neuromuscular diagnostic service.  Patients were investigated traditionally as outlined in a 
recent Neurology review article on the evaluation, diagnosis and management of congenital 
muscular dystrophy (19).  Using this approach, a genetic diagnosis was achieved in only 
34%, despite this cohort being investigated in an expert research centre with access to 
immunohistochemical and Western blot analysis and research-based Sanger sequencing of 
known disease genes.  Of the undiagnosed patients, 33 were investigated by either a NGS 
neuromuscular gene panel or WES and a diagnosis was achieved for 67%.  Overall, a 
diagnosis was achieved for 51% (63/124) of the total cohort; however, 49 undiagnosed 
patients were not available for NGS studies.   If these patients are excluded, a diagnosis was 
achieved for 63/75 (84%) patients investigated by candidate gene sequencing followed by 
WES if negative.  
 
This cohort proves the value of immunohistochemical staining in correctly identifying the 
CMD subtype.  A genetic diagnosis was significantly more likely in patients who could be 
classified in this way.  In our cohort, antibodies to laminin-α2 and collagen VI were the most 
sensitive and specific.  Moderate or severe reduction in α-dystroglycan was less specific, 
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reflecting the technical difficulties of working with antibodies to glycosylated α-dystroglycan 
(20).  However, it is important to consider that in this large cohort an immunohistochemical 
classification, which is then used to guide candidate gene sequencing, could only be made in 
51% (58/114) of patients.   
 
Understanding of the clinical phenotype and natural history of different CMD subtypes is 
improving, such that the more common subtypes (collagen VI, laminin α2, α-
dystroglycanopathies, SEPN1- and LMNA-related muscular dystrophy) should be recognized 
in a specialist neuromuscular clinic.  However, only 35% (43/124) of our cohort had a genetic 
diagnosis confirming one of these subtypes.  This figure is comparable with a UK cohort in 
which these diagnoses comprised 46% of the population (1).   
 
Greater than 50% of the time, the neuromuscular physician is presented with a patient who 
does not fit easily into a CMD subtype on the basis of clinical evaluation and traditional 
diagnostic work up.  As evidenced by the diagnoses in this cohort, there is considerable 
overlap between the clinical and histological features of congenital muscular dystrophy and 
congenital myopathies.  Most patients (73%) with confirmed genetic diagnoses had variants 
in genes recognized to cause congenital muscular dystrophy, but 27% had alternative 
diagnoses.  These included variants in genes better known as causes of congenital myopathy 
and in one case a congenital myasthenic syndrome.   
 
A recently published Neurology review article found Level C evidence for candidate gene 
testing for specific congenital muscular dystrophy subtypes, and recommended considering 
WES as this technology becomes more accessible and affordable (19).  Candidate gene 
sequencing is expensive, time consuming, and yields a diagnosis in less than 50% of patients.  
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The diversity of genetic diagnoses in our cohort, and the presence of a recognizable 
phenotype or immunohistochemical classification to guide candidate gene sequencing in less 
than 50% of the cohort, argues for using NGS as a first line investigation (Figure 5).  This is 
now common practice in our centre. The cost of next generation sequencing is falling rapidly 
and is commercially available in many centres.  Significantly, a neuromuscular gene panel 
would identify 58 of the 63 genetic diagnoses in our cohort.  Two patients with micro-
deletions would not have been detected, reinforcing the importance of CMA in detecting 
large-scale deletions not detected by NGS technology.  
 
The diagnostic yield of prospective investigation with NGS is uncertain.  The results of this 
study suggest it is between 50 and 85%.  The largest previously published neuromuscular 
cohort (incorporating a broader range of disorders with onset of neuromuscular weakness or 
hypotonia less than 5 years of age) found a definitive genetic diagnosis for 21 of 43 (49%) 
using a NGS panel of 579 myopathy genes (21).  In less selective cohorts the diagnosis rates 
are lower; 25% for 2000 consecutive patients referred to Baylor Genetics for WES for 
Mendelian disease (22).   
 
Given the size of our cohort and bias in selecting probands for investigation by a gene panel 
versus WES, this study cannot draw conclusions about the relative efficacy of these different 
approaches.  A previously published neuromuscular cohort study found a higher diagnosis 
rate for a 41 gene panel compared with clinician-requested single gene testing (46% vs 15-
19%) (23).  Coverage of the panel approach, with targeted capture of neuromuscular disease 
genes and Sanger fill-in of low-coverage exons, was better than WES, with 11 to 18% of 
pathogenic variants potentially missed by WES (23).  
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Although a targeted panel approach requires ongoing update to the panel as new genetic 
causes of neuromuscular disease are identified, better coverage makes this approach 
attractive, and we propose that it should be currently considered as the first line investigation.  
Patients who remain without a genetic diagnosis despite investigation with a neuromuscular 
panel should be considered for research-based whole exome or whole genome sequencing, 
where confirming candidate gene pathogenicity will require functional studies, international 
collaboration and identification of further affected patients (Figure 5).  
 
Increasingly, the role of the muscle biopsy and its position in the diagnostic algorithm is 
being questioned.  In our cohort, a genetic diagnosis was more likely in patients with an 
elevated CK, or dystrophic biopsy findings, however, neither was sensitive or specific.  The 
muscle biopsy is expensive, invasive, can be challenging in infants and children with severe 
weakness and impaired respiratory function, and has a risk of a malignant hyperthermia 
reaction for some patients.  In our cohort it was also associated with delay to genetic 
diagnosis. The muscle biopsy will not become obsolete, but should be considered after 
genetic testing, to help confirm the pathogenicity of novel variants by demonstrating reduced 
protein levels or for RNA sequencing or cDNA analysis to prove splice site disruption.  
 
Despite the enormous advances seen in genetic diagnosis over the last 10 years, results from 
our cohort and the current literature, suggests that up to 50% of patients with CMD remain 
without a genetic diagnosis following NGS.  The challenge of neuromuscular genetic 
research now lies with these unsolved families, who may bear variants in genes missed by 
bioinformatics filtering or sequencing coverage, or who have more complex genetic 
abnormalities that may be revealed via whole genome and RNA sequencing.  As the more 
common causes of neuromuscular disease are identified, recognition of rarer cases, of which 
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there may only be one patient in any given cohort, will depend on the strength of 
international collaboration, open access databases and powerful bioinformatics.   
 
Our success rate in diagnosing CMD has doubled over the past 10 years.  As NGS enters 
routine clinical practice, it is transforming the traditional approach to diagnosis and our data 
supports the efficacy, time- and cost- effectiveness of this approach.  Timely diagnosis has 
many benefits including the end of what is often a long diagnostic odyssey and can help 
change the focus from diagnosis to management of the child’s difficulties (24).  Health care 
and medical surveillance for complications can be individualized (11) and families are 
provided with information which can restore reproductive confidence and be used in prenatal 
diagnosis.  The challenge for health care service providers is to now incorporate and 
streamline access to NGS panels for referring clinicians as a first-line diagnostic enquiry.  
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Figure 1: Whole exome sequencing analysis pipeline 
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Figure 2: Cohort ascertainment and investigation  
  124 CMD patients were ascertained.  Conventional investigation was with protein-based screening of muscle biopsy specimens and candidate gene sequencing.  Undiagnosed patients were investigated with Next Generation Sequencing technologies.  11 fetuses and deceased neonates were excluded because they had not been the subject of further investigations, and significant time had elapsed since ascertainment.   * These patients were included in the cohort published by Peat et al, Diagnosis and etiology of congenital muscular dystrophy, Neurology. 2008; 71:312-321  
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Figure 3 (online):  Immunohistochemical analysis, candidate gene sequencing and 
genetic diagnoses  
  
Figure 3 illustrates the classification of patients by immunohistochemical (IHC) analysis and 
diagnoses made by candidate gene sequencing and next generation sequencing (NGS).   
Left panel (IHC classification):  114 probands had immunohistochemical (IHC) analysis 
performed on muscle biopsy specimens.  58 probands were able to be classified on the basis 
of a moderate or severe reduction in collagen VI, laminin-α2 or glycosylated α-dystroglycan. 
56 patients could not be classified by IHC analysis.  Middle panel (Candidate gene 
sequencing):  Candidate gene sequencing was performed on the basis of IHC classification, 
and when unclassified, on the basis of clinical phenotype.  The gene sequenced is indicated in 
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a white box, and the confirmed genetic diagnoses are shown by yellow boxes. The number of 
patients undiagnosed after candidate gene sequencing is shown in a grey circle.  
Right panel (NGS): NGS was performed on the number of patients indicated with a white 
circle.  The confirmed diagnoses are shown in yellow.     
Figure 4:  Heterogeneity of genetic diagnoses in a congenital muscular dystrophy 
cohort 
 
 73% of the cohort had variants in genes previously recognized, or recently described as causes of congenital muscular dystrophy.  17% of patients had variants in genes better recognized as causes of congenital myopathy.  One patient had a congenital myasthenic syndrome with compound heterozygous variants in GFPT1.   * Includes one patient with probable LARGE-CMD, but with only a heterozygous variant detected in LARGE. + Includes one patient with probable LAMA2-CMD, but with only a heterozygous variant in LAMA2. 
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Table 2: Review of genetic diagnoses by muscle biopsy findings and creatine 
kinase levels.   
 Dystrophic Non-dystrophic 
Elevated CK 
36/54 (67%)  Elevated CK (>1000IU/L): 
FKRP, FKTN, POMT1 (2), POMT2 (2), 
POMGNT1, LARGE (2) 
GMPPB (2), LAMA2 (6), 
LMNA, ACTA1 Mild elevation (<1000IU/L): 
COL6A1 (7), COL6A2 (3), COL6A3 (2), LMNA (3), PIGY, SEPN1 
2/5 (40%)  
MICU1, SIL1 
Normal CK 
12/25 (48%)  
COL6A2, COL6A3, 
DNM2, LAMA2, RYR1 
(2), TTN (3), ACTA1, , GFPT1, Candidate 
8/24 (35%)  Microdeletion (2), 
COL6A2, DNM2, 
RYR1, SEPN1, candidate (2) Excluded are 16 patients who either did not have a muscle biopsy, or for whom, the CK result had not been recorded.              
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Figure 5:  Proposed diagnostic algorithm for Congenital Muscular Dystrophy 
 
 
  Proposed diagnosis of suspected congenital muscular dystrophy patients using a targeted next generation sequencing neuromuscular gene panel after exclusion of diagnoses missed by this technology.  Muscle biopsy should be considered in patients undiagnosed by NGS.  CMA, chromosomal microarray; SMA, spinal muscular atrophy; NGS, next generation sequencing; RNA, RNA sequencing 
 
 
